Novartis Ag

Anna Galkin

Scott Glaser

Sarah Rue

Tetsuo Uno

Steven Lee Bender

Shailaja Kasibhatla

Bernhard Hubert Geierstanger

Mark Knuth

Glen Spraggon

Sabine Rottmann

Tracy Charlton

Jian Shi

Michael DiDonato

Alexandra Kraus

Christian Cho-Hua Lee

Xenia Karola Wezler

Yong Jia

Klaus Felix Hartlepp

Christoph Erkel

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Anti-CCR7 antibody drug conjugates

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

Growing community of inventors

Encinitas, CA, United States of America

Anna Galkin